Cosmos Health Inc. has secured an additional 180-day period to regain compliance with the Nasdaq minimum bid price requirement, providing the company time until December 7, 2026, to elevate its stock price. The extension, granted by the Listing Qualifications Department of The Nasdaq Stock Market LLC on June 10, 2026, follows the company's adherence to all other applicable listing standards, specifically the market value of publicly held shares requirement for the Nasdaq Capital Market.

To satisfy the compliance conditions, the closing bid price of Cosmos Health's common stock must maintain at least $1.00 per share for a minimum of ten consecutive business days within the newly granted compliance period. The company stated that its primary strategy focuses on organic growth and operational execution to meet this threshold.

Strategic Approach to Compliance

Cosmos Health emphasized that it does not intend to effect a reverse stock split unless it becomes necessary to maintain its Nasdaq listing. Management views a reverse split as a measure of last resort. The company plans to drive shareholder value through revenue growth, pipeline advancement, and other corporate initiatives.

Greg Siokas, CEO of Cosmos Health, stated that the company's strong preference is to regain compliance without a reverse stock split. He highlighted that the plan is built around executing the business strategy to create real value for shareholders, noting that a reverse split would only be utilized to preserve the listing if absolutely required.

Key Compliance Details

Cosmos Health Inc. announced on June 10, 2026, that its wholly-owned subsidiary Cana Laboratories has secured a three-year contract manufacturing agreement with Verisfield S.A. to produce 3.9 million units of VASCLOR GEST (progesterone) 400mg vaginal pessaries. This partnership marks a strategic expansion for Cana Laboratories into the women's health and reproductive medicine sectors, diversifying its order book across additional customers and therapeutic areas. The agreement entails an annual manufacturing volume of 1.3 million units, with production taking place at Cana's European GMP-certified facilities.

Under the terms of the agreement, Cana will manufacture the product indicated for luteal phase support and as part of assisted reproduction treatment. The pessaries are supplied at a dosage of 400mg per unit, packaged in boxes of 15 pessaries within PVC-PE strips. Verisfield, a specialty pharmaceutical company established in 2000, markets a portfolio of over 60 pharmaceutical products across seven therapeutic categories in Greece and internationally through strategic partners.

Greg Siokas, CEO of Cosmos Health, stated that the agreement represents a further expansion of the company's high-margin contract manufacturing division. He emphasized that the deal diversifies the order book across additional customers and therapeutic areas. Siokas noted that the company is well-positioned to secure new contracts and accelerate growth by continuing to upgrade its European GMP-certified infrastructure and capacity.

Agreement Details

The following table outlines the key specifications of the manufacturing agreement:

Strategic Implications

This agreement broadens Cana's contract manufacturing customer base and enhances its presence in the European pharmaceutical market. By leveraging its European Good Manufacturing Practices (GMP) licensed facilities and European Medicines Agency (EMA) certification, Cosmos Health aims to capitalize on the growing demand for specialized generic and differentiated pharmaceutical products. The company continues to focus on expanding its distribution platform throughout Europe, Asia, and North America.